Johnson & Johnson (NYSE:JNJ) Shares Purchased by Hilton Capital Management LLC

Hilton Capital Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 907.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 75,620 shares of the company’s stock after acquiring an additional 68,116 shares during the quarter. Johnson & Johnson makes up about 1.8% of Hilton Capital Management LLC’s portfolio, making the stock its 17th biggest holding. Hilton Capital Management LLC’s holdings in Johnson & Johnson were worth $9,916,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in JNJ. Tamarack Advisers LP purchased a new stake in Johnson & Johnson during the fourth quarter worth about $18,035,000. Orser Capital Management LLC increased its stake in Johnson & Johnson by 44.2% during the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock worth $272,000 after purchasing an additional 575 shares during the period. S.E.E.D. Planning Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $387,000. Bay Rivers Group purchased a new stake in Johnson & Johnson during the fourth quarter worth about $339,000. Finally, Duff & Phelps Investment Management Co. grew its position in shares of Johnson & Johnson by 1.4% during the fourth quarter. Duff & Phelps Investment Management Co. now owns 29,455 shares of the company’s stock worth $4,297,000 after buying an additional 400 shares in the last quarter. 68.45% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on JNJ. Morgan Stanley boosted their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Credit Suisse Group reaffirmed a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a report on Tuesday, April 28th. Raymond James upped their price target on Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Argus reaffirmed a “buy” rating and issued a $155.00 price target (down from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. Finally, Bank of America raised Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $150.00 to $175.00 in a report on Wednesday, April 22nd. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Johnson & Johnson has an average rating of “Buy” and a consensus target price of $163.47.

Shares of NYSE:JNJ opened at $144.56 on Wednesday. The stock’s 50-day moving average price is $147.76 and its two-hundred day moving average price is $142.57. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The firm has a market cap of $380.36 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 3.14 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The firm had revenue of $20.69 billion for the quarter, compared to analyst estimates of $19.48 billion. During the same period last year, the company earned $2.10 EPS. The firm’s quarterly revenue was up 3.3% on a year-over-year basis. As a group, research analysts forecast that Johnson & Johnson will post 7.68 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.79%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

In other news, Director William D. Perez acquired 500 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were bought at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.27% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is the significance of the death cross?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).